Erudio Healtherudio.com
Sponsor
Pfizer trials: what clinicians said in public
HCP commentary reports on 4 clinical trials sponsored by Pfizer: FOURLIGHT-1, MagnetisMM-6, MEVPRO-1 and SigVie-002. Each covers what clinicians said in public about one trial, on podcasts, videos and posts, every statement linked to its source. Below them, 52 more trials with public commentary and no report yet.
Listed by lead sponsor as registered on ClinicalTrials.gov (Pfizer; Seagen, a wholly owned subsidiary of Pfizer; Seagen Inc.). A trial led by a partner or a research group is on that sponsor's page. Only trials with public clinician commentary found are listed, not every trial the sponsor runs.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| MEVPRO-1 NCT06551324 · Pfizer | metastatic castration-resistant prostate cancer previously treated with abiraterone | Phase 3 | 182 | 18 | Standard | Nov 16, 2026 | Preview |
| FOURLIGHT-1 NCT06105632 · Pfizer | HR-positive/HER2-negative advanced/metastatic breast cancer after CDK4/6 inhibitor-based therapy | Phase 2 | 186 | 60 | Standard | Nov 13, 2026 | Preview |
| SigVie-002 NCT06012435 · Seagen, a wholly owned subsidiary of Pfizer | previously treated non-small cell lung cancer | Phase 3 | 64 | 24 | Focused | Nov 2, 2026 | Preview |
| MagnetisMM-6 NCT05623020 · Pfizer | transplant-ineligible newly diagnosed multiple myeloma | Phase 3 | 326 | 61 | Deep | Oct 24, 2026 | Preview |
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| JAVELIN Bladder 100 NCT02603432 · Pfizer DeepView → | locally advanced or metastatic urothelial carcinoma | Phase 3 | Deep | View | |||
| BREAKWATER NCT04607421 · Pfizer DeepView → | first-line BRAF V600E-mutant metastatic colorectal cancer | Phase 3 | Deep | View | |||
| HER2CLIMB-05 NCT05132582 · Seagen, a wholly owned subsidiary of Pfizer DeepView → | HER2+ metastatic breast cancer (first-line maintenance) | Phase 3 | Deep | View | |||
| HER2CLIMB NCT02614794 · Seagen Inc. DeepView → | HER2-positive unresectable locally advanced or metastatic breast cancer | Phase 2 | Deep | View | |||
| JAVELIN Renal 101 NCT02684006 · Pfizer DeepView → | first-line advanced renal cell carcinoma | Phase 3 | Deep | View | |||
| VERITAC-2 NCT05654623 · Pfizer DeepView → | ER-positive/HER2-negative advanced breast cancer | Phase 3 | Deep | View | |||
| MOUNTAINEER NCT03043313 · Seagen Inc. DeepView → | chemotherapy-refractory HER2-positive RAS wild-type metastatic colorectal cancer | Phase 2 | Deep | View | |||
| MagnetisMM-3 NCT04649359 · Pfizer DeepView → | triple-class refractory multiple myeloma | Phase 2 | Deep | View | |||
| HER2CLIMB-02 NCT03975647 · Seagen, a wholly owned subsidiary of Pfizer DeepView → | previously treated HER2-positive locally advanced/metastatic breast cancer | Phase 3 | Deep | View | |||
| S-TRAC NCT00375674 · Pfizer DeepView → | high-risk locoregional renal cell carcinoma | Phase 3 | Deep | View | |||
| ECHELON-2 NCT01777152 · Seagen Inc. DeepView → | frontline CD30-positive peripheral T-cell lymphoma | Phase 3 | Deep | View | |||
| EMBRACA NCT01945775 · Pfizer DeepView → | germline BRCA-mutated locally advanced or metastatic breast cancer | Phase 3 | Deep | View | |||
| PROFILE 1001 NCT00585195 · Pfizer DeepView → | advanced cancer | Phase 1 | Deep | View | |||
| CROWN NCT03052608 · Pfizer DeepView → | first-line advanced ALK-positive NSCLC | Phase 3 | Deep | View | |||
| PHAROS NCT03915951 · Pfizer DeepView → | BRAF V600E-mutant metastatic non-small cell lung cancer | Phase 2 | Deep | View | |||
| TALAPRO-2 NCT03395197 · Pfizer DeepView → | first-line metastatic castration-resistant prostate cancer | Phase 3 | Deep | View | |||
| innovaTV 301 NCT04697628 · Seagen, a wholly owned subsidiary of Pfizer DeepView → | second- or third-line recurrent or metastatic cervical cancer | Phase 3 | Deep | View | |||
| ECHELON-3 NCT04404283 · Seagen, a wholly owned subsidiary of Pfizer DeepView → | relapsed or refractory diffuse large B-cell lymphoma | Phase 3 | Deep | View | |||
| PROFILE 1014 NCT01154140 · Pfizer DeepView → | first-line ALK-positive advanced non-squamous non-small-cell lung cancer | Phase 3 | Deep | View | |||
| MagnetisMM-1 NCT03269136 · Pfizer DeepView → | relapsed or refractory multiple myeloma | Phase 1 | Deep | View | |||
| FourLight-3 NCT06760637 · Pfizer DeepView → | HR-positive HER2-negative advanced/metastatic breast cancer | Phase 3 | Deep | View | |||
| BEACON CRC NCT02928224 · Pfizer DeepView → | BRAF V600E-mutant metastatic colorectal cancer | Phase 3 | Deep | View | |||
| HER2CLIMB-04 NCT04539938 · Seagen, a wholly owned subsidiary of Pfizer DeepView → | previously treated HER2+ locally-advanced or metastatic breast cancer | Phase 2 | Deep | View | |||
| MOUNTAINEER-03 NCT05253651 · Seagen, a wholly owned subsidiary of Pfizer DeepView → | first-line HER2+ metastatic colorectal cancer | Phase 3 | Deep | View | |||
| SGNTUC-019 NCT04579380 · Seagen, a wholly owned subsidiary of Pfizer DeepView → | previously treated advanced solid tumors with HER2 alterations | Phase 2 | Deep | View | |||
| MEVPRO-2 NCT06629779 · Pfizer DeepView → | metastatic castration-resistant prostate cancer | Phase 3 | Deep | View | |||
| TALAPRO-1 NCT03148795 · Pfizer DeepView → | metastatic castration-resistant prostate cancer with DNA repair alterations | Phase 2 | Deep | View | |||
| MagnetisMM-30 NCT06215118 · Pfizer DeepView → | relapsed or refractory multiple myeloma | Phase 1 | Deep | View | |||
| TALAPRO-3 NCT04821622 · Pfizer StandardView → | DDR gene-mutated metastatic castration-sensitive prostate cancer | Phase 3 | Standard | View | |||
| JAVELIN Medley NCT02554812 · Pfizer StandardView → | advanced malignancies | Phase 1/Phase 2 | Standard | View | |||
| DV-001 NCT05911295 · Seagen, a wholly owned subsidiary of Pfizer StandardView → | untreated HER2-expressing locally advanced or metastatic urothelial carcinoma | Phase 3 | Standard | View | |||
| INO-VATE NCT01564784 · Pfizer StandardView → | relapsed or refractory CD22-positive acute lymphoblastic leukemia | Phase 3 | Standard | View | |||
| SEAMARK NCT05217446 · Pfizer FocusedView → | first-line BRAF V600E-mutant MSI-H/dMMR metastatic colorectal cancer | Phase 2 | Focused | View | |||
| VERITAC-3 NCT05909397 · Pfizer FocusedView → | Not given | Phase 3 | Focused | View | |||
| SGNB6A-001 NCT04389632 · Seagen, a wholly owned subsidiary of Pfizer FocusedView → | advanced solid tumors | Phase 1 | Focused | View | |||
| NCT01970865 NCT01970865 · Pfizer FocusedView → | Not given | Phase 1/Phase 2 | Focused | View | |||
| NCT02952586 NCT02952586 · Pfizer FocusedView → | locally advanced head and neck squamous cell carcinoma | Phase 3 | Focused | View | |||
| MagnetisMM-9 NCT05014412 · Pfizer FocusedView → | relapsed or refractory multiple myeloma | Phase 2 | Focused | View | |||
| MagnetisMM-7 NCT05317416 · Pfizer FocusedView → | newly diagnosed multiple myeloma after autologous stem-cell transplantation | Phase 3 | Focused | View | |||
| Symbiotic-GU-06 NCT07421700 · Pfizer FocusedView → | locally advanced or metastatic urothelial cancer | Phase 1/Phase 2 | Focused | View | |||
| EMBARK NCT02319837 · Pfizer FocusedView → | high-risk biochemically recurrent non-metastatic prostate cancer | Phase 3 | Focused | View | |||
| JAVELIN PARP MEDLEY NCT03330405 · Pfizer FocusedView → | locally advanced or metastatic solid tumors | Phase 1/Phase 2 | Focused | View | |||
| CREST NCT04165317 · Pfizer FocusedView → | Not given | Phase 3 | Focused | View | |||
| MagnetisMM-5 NCT05020236 · Pfizer FocusedView → | relapsed/refractory multiple myeloma | Phase 3 | Focused | View | |||
| MagnetisMM-32 NCT06152575 · Pfizer FocusedView → | relapsed/refractory multiple myeloma with prior anti-CD38 therapy | Phase 3 | Focused | View | |||
| SGN35-027 NCT03646123 · Seagen Inc. FocusedView → | classical Hodgkin lymphoma | Phase 2 | Focused | View | |||
| Symbiotic-Lung-01 NCT07222566 · Pfizer FocusedView → | locally advanced or metastatic non-small cell lung cancer | Phase 3 | Focused | View | |||
| PROSPER NCT02003924 · Pfizer FocusedView → | Not given | Phase 3 | Focused | View | |||
| NCT03530683 NCT03530683 · Pfizer FocusedView → | advanced hematologic malignancies | Phase 1 | Focused | View | |||
| MagnetisMM-2 NCT04798586 · Pfizer FocusedView → | relapsed or refractory multiple myeloma | Phase 1 | Focused | View | |||
| PROACC-1 NCT05546476 · Pfizer FocusedView → | Not given | Phase 2 | Focused | View | |||
| RIVER PDAC NCT06989437 · Pfizer FocusedView → | Not given | Phase 2/Phase 3 | Focused | View | |||